Insight Molecular Diagnostics Inc.
IMDXNASDAQHealthcare● Active
$5.72
+$0.48(+9.16%)
Market Cap$153533168
P/E Ratio—
52W High$8.51
52W Low$2.33
Insight Molecular Diagnostics Inc. (IMDX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMDX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.28
Est. -$0.26 · -7.1%
Revenue
$0.00B
Est. $0.00B · -86.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
IMDX reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.24 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.26 | -$0.28 | -7.1% | $0.00B | $0.00B | -86.0% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -$0.24 | -$0.27 | -13.7% | $0.00B | $0.00B | +299.6% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.24 | -$0.34 | -41.7% | $0.00B | $0.00B | -8.8% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.23 | -$0.30 | -30.4% | $0.00B | $0.00B | +72.7% |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.24 | -$0.26 | -8.3% | $0.00B | $0.00B | +1586.4% |
| ▲ Q1 FY2025 | Mar 24, 2025 | -$0.43 | $0.48 | +211.6% | $0.00B | $0.00B | +837.2% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.44 | -$0.98 | -122.7% | $0.00B | $0.00B | +13.1% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.28
EPS Est.
-$0.26
EPS Surpr.
-7.1%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026Miss
EPS Actual
-$0.27
EPS Est.
-$0.24
EPS Surpr.
-13.7%
Revenue
$0.00B
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.34
EPS Est.
-$0.24
EPS Surpr.
-41.7%
Revenue
$0.00B
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.23
EPS Surpr.
-30.4%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.24
EPS Surpr.
-8.3%
Revenue
$0.00B
Q1 FY2025
Mar 24, 2025Beat
EPS Actual
$0.48
EPS Est.
-$0.43
EPS Surpr.
+211.6%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.98
EPS Est.
-$0.44
EPS Surpr.
-122.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.34 | $-0.19 | $-0.08 | 1 |
| Q3 FY2027 | $-0.37 | $-0.21 | $-0.09 | 1 |
| Q2 FY2027 | $-0.38 | $-0.22 | $-0.09 | 1 |
| Q1 FY2027 | $-0.40 | $-0.23 | $-0.10 | 1 |
| Q4 FY2026 | $-0.37 | $-0.21 | $-0.09 | 1 |
| Q3 FY2026 | $-0.39 | $-0.22 | $-0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -7.1% | $4.98 | $5.10 | +2.41% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -13.7% | $4.14 | $4.11 | -0.72% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -41.7% | $6.24 | $6.80 | +8.97% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -30.4% | $2.57 | $2.61 | +1.56% |
| ▼ Q2 FY2025 | May 12, 2025 | -8.3% | $2.87 | $2.81 | -2.09% |
| ▲ Q1 FY2025 | Mar 24, 2025 | +211.6% | $3.40 | $3.33 | -2.06% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -122.7% | $2.90 | $3.00 | +3.45% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +35.7% | $3.00 | $3.08 | +2.67% |
Q2 FY2026+2.41%
Report Date
May 13, 2026
EPS Beat/Miss
-7.1%
Price Before
$4.98
Price After
$5.10
Q1 FY2026-0.72%
Report Date
Mar 26, 2026
EPS Beat/Miss
-13.7%
Price Before
$4.14
Price After
$4.11
Q4 FY2025+8.97%
Report Date
Nov 10, 2025
EPS Beat/Miss
-41.7%
Price Before
$6.24
Price After
$6.80
Q3 FY2025+1.56%
Report Date
Aug 11, 2025
EPS Beat/Miss
-30.4%
Price Before
$2.57
Price After
$2.61
Q2 FY2025-2.09%
Report Date
May 12, 2025
EPS Beat/Miss
-8.3%
Price Before
$2.87
Price After
$2.81
Q1 FY2025-2.06%
Report Date
Mar 24, 2025
EPS Beat/Miss
+211.6%
Price Before
$3.40
Price After
$3.33
Q4 FY2024+3.45%
Report Date
Nov 12, 2024
EPS Beat/Miss
-122.7%
Price Before
$2.90
Price After
$3.00
Q3 FY2024+2.67%
Report Date
Aug 8, 2024
EPS Beat/Miss
+35.7%
Price Before
$3.00
Price After
$3.08
Avg Beat Reaction+0.30%
Avg Miss Reaction+2.26%
Beat Rate2 / 8 quarters
Largest Move+8.97% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMDX ends December
Insight Molecular Diagnostics Inc. (IMDX) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.28 — missing the analyst consensus of $-0.26 by -7.1%. The next IMDX earnings date is expected around September 1, 2026.
Each quarter, investors track IMDX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMDX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMDX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMDX earnings · 5 questionsInsight Molecular Diagnostics Inc.'s next earnings report is expected around September 1, 2026. IMDX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMDX historically reports after market close (AMC).
IMDX earnings datewhen is IMDX earningsIMDX next earnings datewhen does IMDX report earningsIMDX earnings calendar
▸ Source: FMP · Insight Molecular Diagnostics Inc. SEC filings · US GAAP · Insight Molecular Diagnostics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026